Context Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Context Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$497K	–	494
2021 Q2	$497K	Hold	5,000	–	–	0.05%	320
2021 Q1	$495K	Hold	5,000	–	–	0.05%	294
2020 Q4	$501K	Hold	5,000	–	–	0.07%	166
2020 Q3	$496K	Buy	+5,000	New	+$500K	0.11%	109

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Context Capital Management's JSPR Position: Q3 2021 in Review

Context Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 5,000 shares — an estimated $497K sold.

Context Capital Management first reported a position in JSPR in Q3 2020 and held it in 4 quarters. The position peaked at $501K in Q4 2020. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Context Capital Management reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Context Capital Management sold 5,000 Jasper Therapeutics shares in Q3 2021, an estimated $497K.
Context Capital Management first reported a position in Jasper Therapeutics in Q3 2020 and held it in 4 quarters.
Context Capital Management's Jasper Therapeutics position peaked at $501K in Q4 2020.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Context Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.